Smallpox

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

APSV in Vaccinia Naive Adults

A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

High Dose IMVAMUNE® in Vaccinia-Naive Individuals

Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults

Dryvax Dilution-Prev Vacc Adults

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

MVA Post-Event: Administration Timing and Boost Study

ACAM 3000 MVA at Harvard Medical School

Dressing Preparations for Smallpox

Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT

Human Immune Responses Smallpox

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

Combination Study With MVA BN and Dryvax

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine